论文部分内容阅读
以往认为红系疾病患者骨髓移植(BMT)受到阳制。本文报告4例先天性纯红再障(CPRCA)进行同HLA抗原、混合细胞培养无反应的同胞BMT,4例均在1岁内诊断,需反复输红细胞悬液5年以上。3例BMT后2个月内见源于供体细胞的正常造血,1例在1个月内见供体细胞造血,但2个月内出现排斥反应,第2次BMT后6周出现供体细胞造血,4例BMT后存活520-1320天。 BMT前预处理方案:马抗胸腺细胞球蛋白20mg/kg/日,BMT前9,7,5,3天;马利兰3.0-3.5mg/kg/日,BMT前第9,8,7,6天;甲基苄肼12.5mg/kg/日,BMT前第8,6,4,2天,环磷酰胺50mg/kg/日,BMT前第5,4,3,2天。为预防移植物抗宿主病(GVHD),BMT后开始接受氨甲喋呤10mg/
Bone marrow transplant (BMT) in patients with erythroid disease was previously thought to be positive. In this paper, 4 cases of congenital pure red aplasia (CPRCA) with HLA antigen, mixed cell culture nonresponsive sibling BMT, 4 cases were diagnosed within 1 year, the red blood cell suspension should be repeated over 5 years. See normal hematopoiesis from donor cells within 3 months after BMT, 1 donor hematopoietic within 1 month, rejection within 2 months, donor 6 weeks after 2 nd BMT Hematopoietic cells survived 520-1320 days after 4 cases of BMT. BMT pretreatment program: horse anti-thymocyte globulin 20mg / kg / day, 9,7,5,3 days prior to BMT; 3.0-3.5mg / kg / day of marilan, 9,8,7,6 days before BMT ; Procarbazine 12.5mg / kg / day, BMT before 8,6,4,2 days, cyclophosphamide 50mg / kg / day, 5,4,3,2 days before BMT. To prevent graft versus host disease (GVHD), BMT begins with methotrexate 10 mg /